L
Leslie Cho
Researcher at Cleveland Clinic
Publications - 178
Citations - 6869
Leslie Cho is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 31, co-authored 153 publications receiving 4896 citations. Previous affiliations of Leslie Cho include Loyola University Medical Center & Cleveland Clinic Lerner Research Institute.
Papers
More filters
Journal ArticleDOI
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).
Massimo Piepoli,Arno W. Hoes,Stefan Agewall,Christian Albus,Carlos Brotons,Alberico L. Catapano,Marie-Therese Cooney,Ugo Corrà,Bernard Cosyns,Christi Deaton,Ian D. Graham,Michael Stephen Hall,F. D. Richard Hobbs,Maja-Lisa Løchen,Herbert Löllgen,Pedro Marques-Vidal,Joep Perk,Eva Prescott,Josep Redon,Dimitrios J. Richter,Naveed Sattar,Y.M. Smulders,Monica Tiberi,H. Bart van der Worp,Ineke van Dis,W M Monique Verschuren,Additional Contributor: Simone Binno,Guy De Backer,Marco Roffi,Victor Aboyans,Norbert Bachl,Héctor Bueno,Scipione Carerj,Leslie Cho,John Cox,Johan De Sutter,Günther Egidi,Miles Fisher,Donna Fitzsimons,Oscar H. Franco,Maxime Guenoun,Catriona Jennings,Borut Jug,Paulus Kirchhof,Kornelia Kotseva,Gregory Y.H. Lip,François Mach,Giuseppe Mancia,Franz Martin Bermudo,Alessandro Mezzani,Alexander Niessner,Piotr Ponikowski,Bernhard Rauch,Lars Rydén,Adrienne Stauder,Guillaume Turc,Olov Wiklund,Stephan Windecker,José Luis Zamorano +58 more
Journal ArticleDOI
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls,Stephen J. Nicholls,Rishi Puri,Todd J. Anderson,Christie M. Ballantyne,Leslie Cho,John J.P. Kastelein,Wolfgang Koenig,Wolfgang Koenig,Ransi Somaratne,Helina Kassahun,Jingyuan Yang,Scott M. Wasserman,Rob Scott,Imre Ungi,Jakub Podolec,Antonius Oude Ophuis,Jan H. Cornel,Marilyn Borgman,Danielle M. Brennan,Steven E. Nissen +20 more
TL;DR: Among patients with angiographic coronary disease treated with statins, addition of evolocumab, compared with placebo, resulted in a greater decrease in PAV after 76 weeks of treatment, and further studies are needed to assess the effects of PCSK9 inhibition on clinical outcomes.
Journal Article
2016 ESC guidelines on cardiovascular disease prevention in clinical practice
Piepoli Adgdtmf.,Arno W. Hoes,Stefan Agewall,Christian Albus,Carlos Brotons,Alberico L. Catapano,Marie-Therese Cooney,Ugo Corrà,Bernard Cosyns,Christi Deaton,Ian D. Graham,Michael Stephen Hall,Hobbs Fdr.,Maja-Lisa Løchen,Herbert Löllgen,Pedro Marques-Vidal,Joep Perk,Eva Prescott,Josep Redon,Dimitrios J. Richter,Naveed Sattar,Y.M. Smulders,Monica Tiberi,H B van der Worp,I van Dis,Verschuren Wmm.,Binno Cas.,Backer Rddgd.,Marco Roffi,Victor Aboyans,Norbert Bachl,Héctor Bueno,Scipione Carerj,Leslie Cho,John Cox,Johan De Sutter,Günther Egidi,Miles Fisher,Donna Fitzsimons,Oscar H. Franco,Maxime Guenoun,C Jennings,Borut Jug,Paulus Kirchhof,Kornelia Kotseva,Lip Gyh.,François Mach,Giuseppe Mancia,Franz Martin Bermudo,Alessandro Mezzani,Alexander Niessner,Piotr Ponikowski,Bernhard Rauch,Lars Rydén,Adrienne Stauder,Guillaume Turc,Olov Wiklund,Stephan Windecker,José Luis Zamorano +58 more
Journal ArticleDOI
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance : The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab
Erik S.G. Stroes,David Colquhoun,David R. Sullivan,Fernando Civeira,Robert S. Rosenson,Gerald F. Watts,Eric Bruckert,Leslie Cho,Ricardo Dent,Beat Knusel,Allen Xue,Rob Scott,Scott M. Wasserman,Michael Rocco +13 more
TL;DR: Robust efficacy combined with favorable tolerability makes evolocumab a promising therapy for addressing the largely unmet clinical need in high-risk patients with elevated cholesterol who are statin intolerant.
Journal ArticleDOI
An abundant dysfunctional apolipoprotein A1 in human atheroma
Ying Huang,Joseph A. DiDonato,Bruce S. Levison,Dave Schmitt,Lin Li,Yuping Wu,Jennifer A. Buffa,Timothy Kim,Gary Gerstenecker,Gary Gerstenecker,Xiaodong Gu,Chandra S Kadiyala,Zeneng Wang,Miranda K. Culley,Jennie E. Hazen,Anthony J. DiDonato,Xiaoming Fu,Stela Z Berisha,Dao-Quan Peng,Truc Nguyen,Shaohong Liang,Chia-Chi Chuang,Leslie Cho,Edward F. Plow,Paul L. Fox,Valentin Gogonea,Valentin Gogonea,W.H. Wilson Tang,John S. Parks,Edward A. Fisher,Jonathan D. Smith,Stanley L. Hazen +31 more
TL;DR: A high-affinity monoclonal antibody is developed that specifically recognizes both apoA1 and HDL that have been modified by the MPO-H2O2-Cl− system and demonstrates both a potent proinflammatory activity on endothelial cells and an impaired HDL biogenesis activity in vivo.